Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation - PubMed

Affiliations

• PMID: 25300866
• DOI: 10.1016/j.bbmt.2014.09.030

Free article

Clinical Trial

Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation

Ke Zhao et al. Biol Blood Marrow Transplant. 2015 Jan.

Free article

Abstract

Refractory acute graft-versus-host disease (aGVHD) is a major cause of death after allogeneic hematopoietic stem cell transplantation. This study evaluated the immunomodulation effects of mesenchymal stromal cells (MSCs) from bone marrow of a third-party donor for refractory aGVHD. Forty-seven patients with refractory aGVHD were enrolled: 28 patients receiving MSC and 19 patients without MSC treatment. MSCs were given at a median dose of 1 × 10(6) cells/kg weekly until patients got complete response or received 8 doses of MSCs. After 125 doses of MSCs were administered, with a median of 4 doses (range, 2 to 8) per patient, overall response rate was 75% in the MSC group compared with 42.1% in the non-MSC group (P = .023). The incidence of cytomegalovirus, Epstein-Barr virus infections, and tumor relapse was not different between the 2 groups during aGVHD treatment and follow-up. The incidence and severity of chronic GVHD in the MSC group were lower than those in the non-MSC group (P = .045 and P = .005). The ratio of CD3(+)CD4(+)/CD3(+)CD8(+) T cells, the frequencies of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs), and the levels of signal joint T cell-receptor excision DNA circles (sjTRECs) after MSCs treatment were higher than those pretreatment. MSC-treated patients exhibited higher Tregs frequencies and sjTRECs levels than those in the non-MSC group at 8 and 12 weeks after treatment. MSCs derived from bone marrow of a third-party donor are effective to refractory aGVHD. It might reduce the incidence and severity of chronic GVHD in aGVHD patients by improving thymic function and induction of Tregs but not increase the risks of infections and tumor relapse.

Keywords: Graft-versus-host disease; Hematopoietic stem cell transplantation; Immunomodulation; Mesenchymal stromal cell.

Similar articles

• Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.

  Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sánchez-Guijo F, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19. Biol Blood Marrow Transplant. 2014. PMID: 24952358 Clinical Trial.

• [Clinical observation of mesenchymal stem cell as salvage treatment for refractory acute graft-versus-host disease].

  Zhao K, Huang F, Peng YW, Zhou HS, Fan ZP, Zhang X, Guo XT, Xu N, Sun J, Xiang P, Liu QF. Zhao K, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Feb;34(2):122-6. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23611218 Chinese.

• Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.

  Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D'Amico G, Biondi A, Rambaldi A, Biagi E. Introna M, et al. Biol Blood Marrow Transplant. 2014 Mar;20(3):375-81. doi: 10.1016/j.bbmt.2013.11.033. Epub 2013 Dec 7. Biol Blood Marrow Transplant. 2014. PMID: 24321746 Clinical Trial.

• The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.

  Zhao L, Chen S, Yang P, Cao H, Li L. Zhao L, et al. Stem Cell Res Ther. 2019 Jun 21;10(1):182. doi: 10.1186/s13287-019-1287-9. Stem Cell Res Ther. 2019. PMID: 31227011 Free PMC article. Review.

Cited by

• Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation.

  Podestà MA, Remuzzi G, Casiraghi F. Podestà MA, et al. Front Immunol. 2021 Feb 10;11:618243. doi: 10.3389/fimmu.2020.618243. eCollection 2020. Front Immunol. 2021. PMID: 33643298 Free PMC article. Review.

• [Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation].

  Zhao K, Huang F, Chen XY, Chang Y, Xu N, Shi PC, Liu H, Sun J, Xiang P, Liu QF, Fan ZP. Zhao K, et al. Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):488-493. doi: 10.3760/cma.j.issn.0253-2727.2022.06.008. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35968592 Free PMC article. Chinese.

• Mesenchymal Stem Cell Therapy Overcomes Steroid Resistance in Severe Gastrointestinal Acute Graft-Versus-Host Disease.

  Moritani K, Miyawaki R, Tokuda K, Ochi F, Eguchi-Ishimae M, Tauchi H, Eguchi M, Ishii E, Nagai K. Moritani K, et al. Case Rep Transplant. 2019 May 21;2019:7890673. doi: 10.1155/2019/7890673. eCollection 2019. Case Rep Transplant. 2019. PMID: 31263624 Free PMC article.

• Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.

  Servais S, Baron F, Lechanteur C, Seidel L, Selleslag D, Maertens J, Baudoux E, Zachee P, Van Gelder M, Noens L, Kerre T, Lewalle P, Schroyens W, Ory A, Beguin Y. Servais S, et al. Oncotarget. 2018 Apr 17;9(29):20590-20604. doi: 10.18632/oncotarget.25020. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755674 Free PMC article.

• [Progress of chronic graft-versus-host disease].

  Lei M, Liu L, Wu D. Lei M, et al. Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):79-82. doi: 10.3760/cma.j.issn.0253-2727.2016.01.018. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 26876262 Free PMC article. Chinese. No abstract available.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program